<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753467</url>
  </required_header>
  <id_info>
    <org_study_id>TONG-HBV-0801</org_study_id>
    <nct_id>NCT00753467</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B</brief_title>
  <official_title>Protocol Title: A Phase II Open-labeled Study to Determine the Safety and Preliminary Efficacy of Interferon-gamma 1b (IFN-γ 1b) in Patients With Chronic Hepatitis B Who Are HBV DNA Positive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huntington Medical Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>InterMune</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Huntington Medical Research Institutes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, prospective, two part study evaluating IFN-γ 1b at a dose of 200μg by
      subcutaneous injection every day either alone or in combination with Adefovir dipivoxil or
      Adefovir dipivoxil alone at a dose of 10mg QD in patients with chronic Hepatitis B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After signing the informed consent potential patients will undergo a screening medical
      history, physical examination, and laboratory tests.

      The study will consist of two parts:

        -  Part A: IFN-γ 1b monotherapy

        -  Part B: IFN-γ 1b combination therapy with Adefovir dipivoxil or Adefovir dipivoxil
           monotherapy

      Patients will be enrolled sequentially into to one of three treatment groups. In Part A, ten
      patients will be enrolled and will receive IFN-γ 1b 200μg, administered every day by
      subcutaneous injection for 4 weeks. If HBV DNA is reduced by ≥ 1 log10 copies/ mL in ≥ 30% of
      patients the protocol will proceed to Part B.

      In Part B, twenty patients will be enrolled into two cohorts (total of 10 for each cohort)
      and treated for four weeks. The two cohorts will be administered:

        -  IFN-γ 1b 200μg, administered every day combination therapy with Adefovir dipivoxil (10mg
           QD) or

        -  Adefovir dipivoxil (10mg QD) alone

      On the initial study visit, patients will be given instruction on self injection of IFN-γ 1b
      (if applicable). Patients will be monitored for safety, tolerability, HBV DNA, clinical
      chemistries including a standard panel of liver tests and hematologies throughout the study
      and for the two week post-treatment observation period.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to evaluate the safety and tolerability of IFN-γ 1b either alone or in combination with Adefovir dipivoxil in patients with chronic Hepatitis B.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the changes in serum HBV DNA concentrations following administration of Adefovir dipivoxil alone, IFN-γ 1b either alone or in combination with Adefovir dipivoxil in patients with chronic Hepatitis B.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the changes in liver tests and hematology following administration of Adefovir dipivoxil alone, IFN-γ 1b either alone or in combination with Adefovir dipivoxil in patients with chronic Hepatitis B.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN-γ 1b monotherapy: 200 micro-grams daily for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN-γ 1b 200 micro-grams daily) combination therapy with Adefovir dipivoxil (10 mg daily) for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adefovir dipivoxil monotherapy (10 mg QD) 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFN-γ 1b (Actimmune)</intervention_name>
    <description>IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Interferon gamma</other_name>
    <other_name>Actimmune</other_name>
    <other_name>Immune Interferon</other_name>
    <other_name>IFN-gamma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir dipivoxil</intervention_name>
    <description>Adefovir dipivoxil: 1 tablet of 10mg given orally QD</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Hepsera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFN-γ 1b and Adefovir dipivoxil combination</intervention_name>
    <description>IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Actimmune</other_name>
    <other_name>Interferon gamma</other_name>
    <other_name>IFN gamma</other_name>
    <other_name>Immune Interferon</other_name>
    <other_name>Hepsera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must fulfill all of the following criteria to be eligible for enrollment into the
        study:

          1. Men or women age 18 to 75 years

          2. Chronic hepatitis B infection based on a history of positive anti-HBsAg and positive
             for HBV DNA and with or without elevations in liver tests (test to be repeated on
             screening)

        Exclusion Criteria:

        Patients with any of the following will be excluded from randomization:

          1. Presence of clinically evident cirrhosis including: ascites requiring active diuretic
             therapy, history of or therapy for hepatic encephalopathy, or history of GI variceal
             bleeding

          2. Platelet count &lt; 50,000/mm3

          3. Serum ALT level &gt; 10 times upper limit of normal

          4. Alpha-fetoprotein level ≥ 200 ng/mL or alpha-fetoprotein level between 50-200 ng/mL in
             association with liver ultrasound or other radiographic abnormality suspicious for
             hepatic neoplasm

          5. Serum creatinine level &gt; 1.6 mg/dL

          6. Hematology outside of specified limits: neutrophil count &lt;1000/mm3, hemoglobin &lt;10
             g/dL in males and &lt;9 g/dL in females

          7. Unstable or uncontrolled thyroid disease

          8. Treatment with any interferon-α or nucleoside/tide analog within the previous 4 weeks

          9. Presence of clinically significant cryoglobulinemia (e.g., skin rash, arthritis, or
             renal insufficiency due to cryoglobuliemia)

         10. Presence or history of autoimmune hepatitis, alpha-1 anti-trypsin deficiency,
             hemochromatosis, Wilson's disease, drug- or toxin-induced liver disease,
             alcohol-related liver disease, primary biliary cirrhosis, or sclerosing cholangitis
             (mild-to-moderate steatosis is acceptable)

         11. Chronic hepatitis C infection

         12. Hepatits Delta infection (HDV)

         13. Known history of HIV infection or positive HIV antibody test by Western Blot (test
             performed within 60 days of screening can be used to determine eligibility)

         14. A disease known to cause significant alteration in immunologic function including
             hematological malignancy or autoimmune disorder (e.g. rheumatoid arthritis, systemic
             lupus erythematosis, autoimmune thyroid disease, leukemia, lymphoma, etc)

         15. Concurrent therapy with immunosuppressive drugs or cytotoxic agents such as oral
             prednisone, cyclosporine, azathioprine, or chemotherapeutic agent(s) (e.g.,
             cyclophosphamide, methotrexate, or cancer chemotherapy) or radiation therapy

         16. Behavior that suggests a significant risk of poor compliance including, but not
             limited to:

               1. Illicit drug abuse within the past 3 years

               2. Current or history of alcohol abuse within the past 2 years

         17. Prior treatment with IFN-γ 1b

         18. History of unstable or deteriorating cardiac disease, including but not limited to:

               1. Myocardial infarction, coronary artery bypass surgery, or angioplasty within the
                  past 6 months

               2. Congestive heart failure requiring hospitalization within the past 6 months

               3. Uncontrolled arrhythmias

               4. Transient ischemic attacks (TIAs)

               5. Any cardiac condition that, in the opinion of the site PI, might be significantly
                  exacerbated by flu-like symptoms associated with the administration of IFN γ 1b

         19. Preexisting (within last two years) or active psychiatric condition including severe
             depression, major psychoses, suicidal ideation or suicidal attempts

         20. History of (within last two years) or current neurologic or psychiatric disorder that,
             in the opinion of the site PI, might be exacerbated by flu-like symptoms associated
             with the administration of IFN γ 1b. In addition, patients with the following
             conditions should be excluded:

               1. History of multiple sclerosis

               2. Seizures within the past 2 years

         21. Severe or poorly controlled diabetes

         22. Pregnancy or lactation. Females of childbearing potential are required to have a
             negative urine pregnancy test prior to treatment and must agree to practice abstinence
             or prevent pregnancy by at least a barrier method of birth control for the duration of
             the study

         23. Hemoglobinopthies (e.g. thalassemia, sickle cell disease)

         24. Any serious or chronic disease that, in the opinion of the Principal Investigator
             (PI), may affect the assessment of safety or efficacy parameters. This includes, but
             is not limited to, patients with malignancy who are receiving chemotherapy, chronic
             obstructive pulmonary disease or asthma requiring maintenance oral steroids, or active
             kidney disease

         25. Any condition which, in the opinion of the site PI, is likely to result in the death
             of the patient within the next year

         26. Patients who, in the opinion of the site PI, are not suitable candidates for
             enrollment or would not comply with the requirements of the study

         27. Patients who have had a liver transplant

         28. Patients who have Adefovir mutations on baseline tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myron J Tong, Phd, MD</last_name>
    <role>Study Chair</role>
    <affiliation>HMRI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huntington Medical Research Institutes</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lori Tong, RN</last_name>
      <phone>626-397-5827</phone>
      <email>ltong@hmri.org</email>
    </contact>
    <investigator>
      <last_name>Myron J Tong, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hmri.org/</url>
    <description>Huntington Medical Research Institutes</description>
  </link>
  <reference>
    <citation>Parvez MK, Sehgal D, Sarin SK, Basir SF, Jameel S. Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma. World J Gastroenterol. 2006 May 21;12(19):3006-14.</citation>
    <PMID>16718779</PMID>
  </reference>
  <reference>
    <citation>Lau JY, Lai CL, Wu PC, Chung HT, Lok AS, Lin HJ. A randomised controlled trial of recombinant interferon-gamma in Chinese patients with chronic hepatitis B virus infection. J Med Virol. 1991 Jul;34(3):184-7.</citation>
    <PMID>1919540</PMID>
  </reference>
  <reference>
    <citation>Marcellin P, Loriot MA, Boyer N, Martinot-Peignoux M, Degott C, Degos F, Brandely M, Lenfant B, Benhamou JP. Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects. Hepatology. 1990 Jul;12(1):155-8.</citation>
    <PMID>2115494</PMID>
  </reference>
  <results_reference>
    <citation>Narayan R, Buronfosse T, Schultz U, Chevallier-Gueyron P, Guerret S, Chevallier M, Saade F, Ndeboko B, Trepo C, Zoulim F, Cova L. Rise in gamma interferon expression during resolution of duck hepatitis B virus infection. J Gen Virol. 2006 Nov;87(Pt 11):3225-32.</citation>
    <PMID>17030856</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang J, Michalak TI. Inhibition by woodchuck hepatitis virus of class I major histocompatibility complex presentation on hepatocytes is mediated by virus envelope pre-S2 protein and can be reversed by treatment with gamma interferon. J Virol. 2006 Sep;80(17):8541-53.</citation>
    <PMID>16912304</PMID>
  </results_reference>
  <results_reference>
    <citation>Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9913-7. Epub 2005 Jul 1.</citation>
    <PMID>15994231</PMID>
  </results_reference>
  <results_reference>
    <citation>Park SG, Ryu HM, Lim SO, Kim YI, Hwang SB, Jung G. Interferon-gamma inhibits hepatitis B virus-induced NF-kappaB activation through nuclear localization of NF-kappaB-inducing kinase. Gastroenterology. 2005 Jun;128(7):2042-53.</citation>
    <PMID>15940636</PMID>
  </results_reference>
  <results_reference>
    <citation>Bissett J, Eisenberg M, Gregory P, Robinson WS, Merigan TC. Recombinant fibroblast interferon and immune interferon for treating chronic hepatitis B virus infection: patients' tolerance and the effect on viral markers. J Infect Dis. 1988 May;157(5):1076-80.</citation>
    <PMID>3129521</PMID>
  </results_reference>
  <results_reference>
    <citation>Porres JC, Mora I, Gutiez J, Bartolome J, Quiroga JA, Bas C, Compernolle C, Ordi J, Chocarro A, Carreño V. Antiviral effect of recombinant gamma interferon in chronic hepatitis B virus infection: a pilot study. Hepatogastroenterology. 1988 Feb;35(1):5-9.</citation>
    <PMID>2452123</PMID>
  </results_reference>
  <results_reference>
    <citation>Di Bisceglie AM, Rustgi VK, Kassianides C, Lisker-Melman M, Park Y, Waggoner JG, Hoofnagle JH. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology. 1990 Feb;11(2):266-70.</citation>
    <PMID>2106474</PMID>
  </results_reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>October 20, 2010</last_update_submitted>
  <last_update_submitted_qc>October 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Myron Tong, PhD, MD</name_title>
    <organization>HMRI</organization>
  </responsible_party>
  <keyword>HBV</keyword>
  <keyword>Treatment</keyword>
  <keyword>Interferon-gamma</keyword>
  <keyword>combination</keyword>
  <keyword>Hepsera</keyword>
  <keyword>Actimmune</keyword>
  <keyword>HBV DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

